Michael M Mendelson1, Todd Regh2, James Chan2, Annette Baker3, Heather Harker Ryan3, Nicole Palumbo3, Philip K Johnson3, Suzanne Griggs3, Meera Boghani4, Nirav K Desai5, Elizabeth Yellen6, Lucy Buckley3, Matthew W Gillman7, Justin P Zachariah3, Dionne Graham2, Sarah D de Ferranti3. 1. Department of Cardiology, Boston Children's Hospital, Boston, MA; Boston University School of Medicine, Boston University, Boston, MA. Electronic address: Michael.Mendelson@cardio.chboston.org. 2. Institute for Relevant Clinical Data Analytics (IRCDA), Boston Children's Hospital, Boston, MA. 3. Department of Cardiology, Boston Children's Hospital, Boston, MA. 4. Department of Cardiology, Boston Children's Hospital, Boston, MA; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA. 5. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA. 6. Department of Cardiology, Boston Children's Hospital, Boston, MA; Boston University School of Medicine, Boston University, Boston, MA. 7. Department of Cardiology, Boston Children's Hospital, Boston, MA; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA.
Abstract
OBJECTIVE: To determine the real-world effectiveness of statins and impact of baseline factors on low-density lipoprotein cholesterol (LDL-C) reduction among children and adolescents. STUDY DESIGN: We analyzed data prospectively collected from a quality improvement initiative in the Boston Children's Hospital Preventive Cardiology Program. We included patients ≤21 years of age initiated on statins between September 2010 and March 2014. The primary outcome was first achieving goal LDL-C, defined as <130 mg/dL, or <100 mg/dL with high-level risk factors (eg, diabetes, etc). Cox proportional hazards models were used to assess the impact of baseline clinical and lifestyle factors. RESULTS: Among the 1521 pediatric patients evaluated in 3813 clinical encounters over 3.5 years, 97 patients (6.3%) were started on statin therapy and had follow-up data (median age 14 [IQR 7] years, 54% were female, and 24% obese, 62% with at least one lifestyle risk factor). The median baseline LDL-C was 215 (IQR 78) mg/dL, and median follow-up after starting statin was 1 (IQR 1.3) year. The cumulative probability of achieving LDL-C goal within 1 year was 60% (95% CI 47-69). A lower probability of achieving LDL-C goals was associated with male sex (HR 0.5 [95% CI 0.3-0.8]) and higher baseline LDL-C (HR 0.92 [95% CI 0.87-0.98] per 10 mg/dL), but not age, body mass index percentile, lifestyle factors, or family history. CONCLUSIONS: The majority of pediatric patients started on statins reached LDL-C treatment goals within 1 year. Male patients and those with greater baseline LDL-C were less likely to be successful and may require increased support. Published by Elsevier Inc.
OBJECTIVE: To determine the real-world effectiveness of statins and impact of baseline factors on low-density lipoprotein cholesterol (LDL-C) reduction among children and adolescents. STUDY DESIGN: We analyzed data prospectively collected from a quality improvement initiative in the Boston Children's Hospital Preventive Cardiology Program. We included patients ≤21 years of age initiated on statins between September 2010 and March 2014. The primary outcome was first achieving goal LDL-C, defined as <130 mg/dL, or <100 mg/dL with high-level risk factors (eg, diabetes, etc). Cox proportional hazards models were used to assess the impact of baseline clinical and lifestyle factors. RESULTS: Among the 1521 pediatric patients evaluated in 3813 clinical encounters over 3.5 years, 97 patients (6.3%) were started on statin therapy and had follow-up data (median age 14 [IQR 7] years, 54% were female, and 24% obese, 62% with at least one lifestyle risk factor). The median baseline LDL-C was 215 (IQR 78) mg/dL, and median follow-up after starting statin was 1 (IQR 1.3) year. The cumulative probability of achieving LDL-C goal within 1 year was 60% (95% CI 47-69). A lower probability of achieving LDL-C goals was associated with male sex (HR 0.5 [95% CI 0.3-0.8]) and higher baseline LDL-C (HR 0.92 [95% CI 0.87-0.98] per 10 mg/dL), but not age, body mass index percentile, lifestyle factors, or family history. CONCLUSIONS: The majority of pediatric patients started on statins reached LDL-C treatment goals within 1 year. Male patients and those with greater baseline LDL-C were less likely to be successful and may require increased support. Published by Elsevier Inc.
Authors: J Wouter Jukema; Cheng-Wen Chiang; Jean Ferrières; Raul D Santos; Juan Verdejo; David D Waters; Michael Messig; Lisa Tarasenko Journal: Curr Med Res Opin Date: 2010-09-29 Impact factor: 2.580
Authors: Ann Marie Navar-Boggan; Eric D Peterson; Ralph B D'Agostino; Benjamin Neely; Allan D Sniderman; Michael J Pencina Journal: Circulation Date: 2015-01-26 Impact factor: 29.690
Authors: Albert Wiegman; Barbara A Hutten; Eric de Groot; Jessica Rodenburg; Henk D Bakker; Harry R Büller; Eric J G Sijbrands; John J P Kastelein Journal: JAMA Date: 2004-07-21 Impact factor: 56.272
Authors: K Pyörälä; S Lehto; D De Bacquer; J De Sutter; S Sans; U Keil; D Wood; G De Backer Journal: Diabetologia Date: 2004-07-02 Impact factor: 10.122
Authors: Rae-Ellen W Kavey; Cedric Manlhiot; Kyle Runeckles; Tanveer Collins; Samuel S Gidding; Matthew Demczko; Sarah Clauss; Ashraf S Harahsheh; Michele Mietus-Syder; Michael Khoury; Nicolas Madsen; Brian W McCrindle Journal: CJC Open Date: 2020-06-06